Digitalis Ventures — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Eden Brew develops food and supplementation products designed to deliver nutrition in natural forms that align with how the human body processes nutrients, with a focus on sustainable scaling and long-term health support.
BiotechDeep TechFoodTechHealthtechImpact & Social Good
Co-investorsBreakthrough VictoriaMain Sequence VenturesPossible VenturesRadar Ventures
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+4 more
Smalls produces fresh, gently cooked cat food made to resemble home-prepared meals, differentiating itself from conventional pet food manufacturers by using minimal processing.
Direct to ConsumerFoodTech
Matthew Michaelson(Founder)in
Co-investorsCompanion FundEastward Capital PartnersEvolution VC PartnersFounder CollectiveImaginary Venture CapitalLeft Lane Capital+3 more
.png)
T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, GB
Co-investorsCambridge Innovation CapitalF-Prime CapitalSanofi VenturesSofinnova Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.